Journal of Shandong University (Health Sciences) ›› 2022, Vol. 60 ›› Issue (7): 110-117.doi: 10.6040/j.issn.1671-7554.0.2021.1306

Previous Articles     Next Articles

Efficacy of DC-CIK cells combined with EGFR-TKI for 35 elderly patients with advanced EGFR-mutant lung cancer

WANG Fuli1, SUN Yinping1, QIN Jie2, RONG Jiansheng3   

  1. 1. Department of Oncology, Zibo Central Hospital, Zibo 255000, Shandong, China;
    2. Department of Oncology, Gaoqing Peoples Hospital, Gaoqing 256300, Shandong, China;
    3. Department of Pathology, Zibo Central Hospital, Zibo 255000, Shandong, China
  • Published:2022-07-27

PDF (PC)

54

Abstract: Objective To investigate the clinical efficacy of dendritic cells-cytokine-induced killer cells(DC-CIK cells)combined with epidermal growth factor receptor-tyrosine kinase inhibitor(EGRF-TKI)for elderly patients with advanced EGFR-mutant lung cancer. Methods A total of 70 patients with stage IV lung cancer were divided into treatment group and control group. In the treatment group, 35 patients received DC-CIK cell therapy combined with gefitinib or erlotinib targeted therapy. In the control group, 35 patients received gefitinib or erlotinib targeted therapy. Results The disease control rate(DCR)of the treatment group and control group were 88.6% and 68.6%, respectively, with significant difference(P=0.041). The improvement rate of patients quality of life was significantly higher in the treatment group than in the control group(71.4% vs 45.7%, P=0.029). The 1-year, 2-year, and 3-year overall survival(OS)rates of the treatment group and control group were 62.9% vs 57.1%, 37.1% vs 31.4%, and 8.6% vs 2.9%, respectively, with no significant differences(P=0.217). The 1-year, 2-year, and 3-year progression-free survival(PFS)rates of the treatment group and control group were 57.1% vs 31.4%, 20.0% vs 5.7%, and 2.9% vs 0, respectively, with significant differences(P=0.005). Multivariate analysis showed that patients with adenocarcinoma(HR=0.178, 95%CI: 0.061-0.523)and well-differentiated cancer(HR=0.058, 95%CI: 0.015-0.228)had longer OS, and patients with adenocarcinoma(HR=0.271, 95%CI: 0.094-0.777)and well-differentiated cancer(HR=0.089, 95%CI: 0.029-0.272)also had longer PFS. There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion DC-CIK cells combined with EGRF-TKI can improve the disease control rate and patients quality of life, and prolong the PFS in elderly patients with advanced EGFR-mutant lung cancer.

Key words: Lung cancer, Targeted therapy, Dendritic cells, Cytokine-induced killer cells, Gefitinib, Erlotinib

CLC Number: 

  • R734
[1] Patel SA, Weiss J. Advances in the treatment of non-small cell lung cancer: immunotherapy[J]. Clin Chest Med, 2020, 41(2): 237-247.
[2] Wu F, Wang L, Zhou C. Lung cancer in China: current and prospect[J]. Curr Opin Oncol, 2021, 33(1): 40-46.
[3] Leighl NB, Karaseva N, Nakagawa K, et al. Patient-reported outcomes from FLAURA: osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer[J]. Eur J Cancer, 2020, 125: 49-57. doi: 10.1016/j.ejca.2019.11.006.
[4] 王建丽,王筱静,孙玉莲,等.吉非替尼联合化疗治疗50例晚期非小细胞肺癌患者的疗效[J].山东大学学报(医学版),2019, 57(11): 20-26. WANG Jianli, WANG Xiaojing, SUN Yulian, et al. Clinical effect of gefitinib combined with chemotherapy on patients with advanced non-small cell lung cancer[J]. Journal of Shandong University(Health Sciences), 2019, 57(11): 20-26.
[5] Liu YF, Liu HB, Liu HS, et al. Dendritic cell-activated cytokine-induced killer cell-mediated immunotherapy is safe and effective for cancer patients >65 years old[J]. Oncol Lett, 2016, 12(6): 5205-5210.
[6] Wylie B, Macri C, Mintern JD, et al. Dendritic cells and cancer: from biology to therapeutic intervention [J]. Cancers(Basel), 2019, 11(4): 521.
[7] Gardner A, de Mingo Pulido A, Ruffell B. Dendritic cells and their role in immunotherapy[J]. Front Immunol, 2020, 11: 924. doi: 10.3389/fimmu.2020.00924.
[8] Cao J, Kong FH, Liu X, et al. Immunotherapy with dendritic cells and cytokine-induced killer cells for hepatocellular carcinoma: a meta-analysis[J]. World J Gastroenterol, 2019, 25(27): 3649-3663.
[9] Hung LVM, Ngo HT, Van Pham P. Clinical trials with cytokine-induced killer cells and CAR-T cell transplantation for non-small cell lung cancer treatment[J]. Adv Exp Med Biol, 2020, 1292:113-130. doi: 10.1007/5584_2020_522.
[10] Kim JH, Min SJ, Jang HJ, et al. Comparison of RECIST 1.0 and RECIST 1.1 in patients with metastatic cancer: a pooled analysis[J]. J Cancer, 2015, 6(4): 387-393.
[11] 谭诗生,李杭,罗健,等.欧洲癌症研究与治疗组织研制的生活质量核心调查问卷第3版中文版:生活质量调查问卷测评[J].中国临床康复,2006,10(4):23-27. TAN Shisheng, LI Hang, LUO Jian, et al. Assessment on the standard Chinese version of quality of life core questionnaire version 3.0 designed by European Organization for Reasearch and Treatment of Cancer[J]. Chinese Journal of Clinical Rehabilitation, 2006, 10(4): 23-27.
[12] Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J]. N Engl J Med, 2009, 361(10): 947-957.
[13] Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer(OPTIMAL, CTONC-0802): a multicentre, open-label, randomised, phase 3 study[J]. Lancet Oncol, 2011, 12(8): 735-742.
[14] Takahashi K, Saito H, Hasegawa Y, et al. First-line gefitinib therapy for elderly patients with non-small cell lung cancer harboring EGFR mutation: Central Japan Lung Study Group 0901[J]. Cancer Chemother Pharmaco, 2014, l74(4): 721-727.
[15] Inoue Y, Inui N, Asada K, et al. Phase II study of erlotinib in elderly patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations[J]. Cancer Chemother Pharmacol, 2015, 76(1): 155-161.
[16] Kashiwabara K, Fujii S, Tsumura S, et al. Overall survival of super-elderly(85 years or older)advanced non-small cell lung cancer patients with active epidermal growth factor receptor mutations receiving first-line gefitinib therapy: a single-institute retrospective study[J]. J Cancer Res Clin Oncol, 2021, 147(1): 287-293.
[17] Hirsch FR, Sequist LV, Gore I, et al. Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: results from the US IRESSA clinical access program(ICAP)[J]. Cancer, 2018, 124(11): 2407-2414.
[18] Roberto RC, Walter PD. Targeted therapy and checkpoint immunotherapy in lung cancer[J]. Surg Pathol Clin, 2020, 13(1): 17-33.
[19] 于金明,颜薇薇,陈大卫.肺癌放射免疫新实践[J].山东大学学报(医学版),2021,59(9):1-8. YU Jinming, YAN Weiwei, CHEN Dawei. New practice of radio-immunotherapy for lung cancer[J]. Journal of Shandong University(Health Sciences), 2021, 59(9): 1-8.
[20] Scheper W, Kelderman S, Fanchi LF, et al. Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers[J]. Nat Med, 2019, 25(1): 89-94.
[21] Wang S, Wang X, Zhou X, et al. DC-CIK as a widely applicable cancer immunotherapy [J]. Expert Opin Biol Ther, 2020, 20(6): 601-607.
[22] Zhao Y, Qiao G, Wang X, et al. Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer(NSCLC)patients: a prospective patients preference-based study(PPPS)[J]. Clin Transl Oncol, 2019, 21(6): 721-728.
[23] Solmaz S, Nazila A, Behzad M, et al. Promising immunotherapy: highlighting cytokine-induced killer cells[J]. J Cell Biochem, 2019, 120(6): 8863-8883.
[24] Wang L, Dai Y, Zhu F, et al. Efficacy of DC-CIK-based immunotherapy combined with chemotherapy in the treatment of intermediate to advanced non-small cell lung cancer[J]. Am J Transl Res, 2021, 13(11): 13076-13083.
[25] Song HP, Liu SJ, Zhao ZY, et al. Increased cycles of DC/CIK immunotherapy decreases frequency of Tregs in patients with resected NSCLC[J]. Int Immunopharmacol, 2017, 52: 197-202. doi: 10.1016/j.intimp.2017.09.014.
[26] Xiao Z, Wang CQ, Zhou MH, et al. The antitumor immunity and tumor responses of chemotherapy with or without DC-CIK for non-small-cell lung cancer in China: a meta-analysis of 28 randomized controlled trials[J]. J Immunol Res, 2018,13:1-18. doi: 10.1155/2018/9081938.
[27] Zhu XP, Xu YH, Zhou J, et al. A clinical study evaluating dendritic and cytokine-induced killer cells combined with concurrent radiochemotherapy for stage IIIB non-small cell lung cancer[J]. Genet Mol Res, 2015, 14(3): 10228-10235.
[1] HAN Jing, JIA Chunling. Effects of periodontal basic therapy on postoperative pneumonia in patients with lung cancer before thoracic surgery [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 113-118.
[2] GAO Zhongxia, ZHANG Ming, FAN Mingde, TAN Chenyang, WANG Mengdi, WANG Chao, FAN Yuefei, DING Shouluan, WANG Chengwei. Efficacy and prognostic factors of gamma knife in treating 81 cases of brain metastases from lung cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(8): 44-49.
[3] XIANG Yujiao, LIU Qiang, LIU Lu, SHI Yan. Mechanism of abnormal immune response of dendritic cells in immune thrombocytopenia [J]. Journal of Shandong University (Health Sciences), 2022, 60(7): 89-97.
[4] QIN Jing, YANG Fei, CHEN Qian, XIA Handai, LIU Yanguo, WANG Xiuwen. A network meta-analysis of first-line treatment options for patients with advanced driver-gene wild-type and PD-L1 negative non-squamous non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(7): 74-82.
[5] CHEN Zhaobo, FANG Min, XUE Haoran, LIU Chunyan. Deubiquitinase USP35 promotes the cells migration and invasion of non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(4): 30-37.
[6] GAO Huijiang, WEI Yucheng. Minimally invasive sleeve lobectomy: opportunities and challenges in the era of immunotherapy [J]. Journal of Shandong University (Health Sciences), 2022, 60(11): 23-27.
[7] PENG Yue, LIU Lei, LI Yuan, BIE Fenglong, ZHOU Bolun, LI Runze, JI Ying, BAI Guangyu, TAN Fengwei, GAO Yushun, MU Juwei, XUE Qi, QIU Bin, GAO Shugeng. Comprehensive application of anatomical partial lobectomy and enhanced recovery after surgery [J]. Journal of Shandong University (Health Sciences), 2022, 60(11): 44-53.
[8] GAO Shugeng. Application of enhanced recovery after surgery in perioperative management of lung cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(11): 1-10.
[9] HAN Dingpei, YAN Yue, CAO Yuqin, SUN Xin, HU Yanxia, WANG Minxian, LUO Yan, SHI Yongmei, XIE Qing, HANG Junbiao, LI Hecheng. Expert consensus of Ruijin Hospital on the concept of enhanced recovery after surgery in the clinical practice of thoracic surgery [J]. Journal of Shandong University (Health Sciences), 2022, 60(11): 11-16.
[10] LIU Huining, PENG Jun, REN Yingchun, YANG Guang, WANG Wenhao, LIU Jinfeng, TIAN Qing. Comparison of 34 cases of thoracoscopic wedge resection and 21 cases of segmental resection for stage ⅠA1 non-small cell lung cancer in area P [J]. Journal of Shandong University (Health Sciences), 2022, 60(11): 38-43.
[11] DING Zichen, WANG Haohua, ZHOU Liwen, CONG Huiwen, LI Chengsheng, BAO Qihan, YANG Yi, WANG Lianyuan, WANG Suzhen, SHI Fuyan. Study on the individualized efficacy for non-small cell lung cancer patients based on Bayesian Additive Regression Tree model [J]. Journal of Shandong University (Health Sciences), 2022, 60(10): 92-98.
[12] YU Jinming, YAN Weiwei, CHEN Dawei. New practice of radio-immunotherapy for lung cancer [J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 1-8.
[13] Chuanzhu YAN,Wei WANG,Kunqian JI,Yuying ZHAO. Mitochondrial dysfunction and related brain diseases [J]. Journal of Shandong University (Health Sciences), 2020, 1(8): 34-41.
[14] Anjing CHEN,Xun ZHANG. The new strategies of targeting SUMOylation in the treatment of glioma [J]. Journal of Shandong University (Health Sciences), 2020, 1(8): 88-94.
[15] ZHANG Yu, TANG Xing, MA Haitao, JIANG Wei. Value of indocyanine green fluorescence in thoracoscopic segmentectomy [J]. Journal of Shandong University (Health Sciences), 2020, 58(12): 38-42.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] SUO Dongyang, SHEN Fei, GUO Hao, LIU Lichang, YANG Huimin, YANG Xiangdong. Expression and mechanism of Tim-3 in animal model of drug-induced acute kidney injury[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 1 -6 .
[2] MA Qingyuan, PU Peidong, HAN Fei, WANG Chao, ZHU Zhoujun, WANG Weishan, SHI Chenhui. Effect of miR-27b-3p regulating SMAD1 on osteosarcoma cell proliferation, migration and invasion[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 32 -37 .
[3] LONG Tingting, XIE Ming, ZHOU Lu, ZHU Junde. Effect of Noggin protein on learning and memory abilities and the dentate gyrus structure after cerebral ischemia reperfusion injury in mice[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 15 -23 .
[4] LI Ning, LI Juan, XIE Yan, LI Peilong, WANG Yunshan, DU Lutao, WANG Chuanxin. Expression of LncRNA AL109955.1 in 80 cases of colorectal cancer and its effect on cell proliferation, migration and invasion[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 38 -46 .
[5] ZHANG Baowen, LEI Xiangli, LI Jinna, LUO Xiangjun, ZOU Rong. miR-21-5p targeted TIMP3 to inhibit proliferation and extracellular matrix accumulation of mesangial cells in Type II diabetic nephropathy mice[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 7 -14 .
[6] FU Jieqi, ZHANG Man, ZHANG Xiaolu, LI Hui, CHEN Hong. Molecular mechanism of Toll-like receptor 4 in the aggravation of blood lipid accumulation by inhibiting the peroxisome proliferator-activate receptor γ[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 24 -31 .
[7] XU Yuxiang, LIU Yudong, ZHANG Peng, DUAN Ruisheng. A retrospective analysis of risk factors of cerebral microbleeds in 101 patients with cerebral small vessel disease[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 67 -71 .
[8] DING Xiangyun, YU Qingmei, ZHANG Wenfang, ZHUANG Yuan, HAO Jing. Correlation of the expression of insulin-like growth factor II in granulosa cells and ovulation induction outcomes of 84 patients with polycystic ovary syndrome[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 60 -66 .
[9] SHI Shuang, LI Juan, MI Qi, WANG Yunshan, DU Lutao, WANG Chuanxin. Construction and application of a miRNAs prognostic risk assessment model of gastric cancer[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 47 -52 .
[10] XIAO Juan, XIAO Qiang, CONG Wei, LI Ting, DING Shouluan, ZHANG Yuan, SHAO Chunchun, WU Mei, LIU Jianing, JIA Hongying. Comparison of diagnostic efficacy of two kinds of thyroid imagine reporting and data systems[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 53 -59 .
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd